Hansa Biopharma appoints Fredrik Röök as VP Business Development

pharmafile | June 11, 2026 | Appointment | Business Development Hansa Biopharma 

Hansa Biopharma has announced that Fredrik Röök has been appointed as VP Business Development, as of 17 August. Röök will report to CEO Renée Aguiar-Lucander.

Röök brings more than 20 years of experience in business development, licensing and strategic transactions across the global life science industry. He joins Hansa from AstraZeneca, where he served as Senior Director, Global Business Development, leading complex partnering activities including M&A, in- and out-licensing, divestments and strategic collaborations. He has a strong track record of executing transactions across all stages, from early innovation to commercial assets, across pharma, biotech, and venture-backed environments.

Renée Aguiar-Lucander, CEO of Hansa Biopharma said “Mr Röök is a highly qualified and proven business development leader with deep expertise in complex transactions, a strong strategic mindset and a broad global network. He will play a key role as we advance our pipeline and pursue new strategic opportunities.”

Advertisement

Related Content

Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy

Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the …

Hansa Biopharma to host investor event on Guillain-Barré Syndrome to accelerate research

Hansa Biopharma (Hansa) will host a virtual investor event on Guillain-Barré syndrome (GBS) on 16 …

Hansa Biopharma data demonstrates potential of imlifidase in Guillain-Barré syndrome

Hansa Biopharma will present data from its 15-HMedIdeS-09 phase 2 study of imlifidase for treating …

The Gateway to Local Adoption Series

Latest content